Metropolitan Life Insurance CO Tarsus Pharmaceuticals, Inc. Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$14.75 - $24.62 $6,165 - $10,291	418 Added 33.74%	1,657 $29,000
Q2 2022 Mar 30, 2023	SELL	$11.08 - $19.08 $11,434 - $19,690	-1,032 Reduced 45.44%	1,239 $18,000
Q2 2022 Aug 11, 2022	BUY	$11.08 - $19.08 $13,728 - $23,640	1,239 New	1,239 $18,000
Q1 2021 May 14, 2021	SELL	$27.37 - $47.25 $62,157 - $107,304	-2,271 Closed	0 $0
Q4 2020 Jun 22, 2023	BUY	$19.17 - $49.62 $19,783 - $51,207	1,032 Added 83.29%	2,271 $93,000
Q4 2020 Mar 30, 2023	BUY	$19.17 - $49.62 $19,783 - $51,207	1,032 Added 83.29%	2,271 $93,000
Q4 2020 Feb 16, 2021	BUY	$19.17 - $49.62 $43,535 - $112,687	2,271 New	2,271 $94,000

170

43.3M

484K

4.1K

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.24B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.